Mary Kay Fenton

CIK: 0001378589

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CGEM

Cullinan Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CGEM
Cullinan Therapeutics, Inc.
Jun 30, 2026
Award(A)
Direct
1.5K shares at avg. $8.60$13K
CGEM
Cullinan Therapeutics, Inc.
Feb 20, 2026
Sale(S)
Direct
4.4K shares at avg. $13.62$60K
CGEM
Cullinan Therapeutics, Inc.
Feb 18, 2026
Award(A)
Direct
68.8K shares-
CGEM
Cullinan Therapeutics, Inc.
Dec 31, 2025
Award(A)
Direct
27 shares at avg. $6.49$175.23
CGEM
Cullinan Therapeutics, Inc.
Feb 19, 2025
Award(A)
Direct
60K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	CGEM Cullinan Therapeutics, Inc.	Award(A)	1,541	$8.60	$13,253	Direct
Feb 20, 2026	CGEM Cullinan Therapeutics, Inc.	Sale(S)	4,398	$13.62	$59,901	Direct
Feb 18, 2026	CGEM Cullinan Therapeutics, Inc.	Award(A)	68,750	-	$0	Direct
Dec 31, 2025	CGEM Cullinan Therapeutics, Inc.	Award(A)	27	$6.49	$175	Direct
Feb 19, 2025	CGEM Cullinan Therapeutics, Inc.	Award(A)	60,000	-	-	Direct

1-5 of 5 transactions

About Fenton Mary Kay

Fenton Mary Kay (SEC CIK 0001378589) files insider reports with the SEC as Chief Financial Officer of Cullinan Therapeutics, Inc. (CGEM).

Signal8 holds 5 ownership filings by Fenton Mary Kay, all Form 4s, filed between Feb 21, 2025 and Jul 2, 2026. Those filings report 5 transactions, from Feb 19, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Fenton Mary Kay's filings is in CAMBRIDGE, MA.

Recent filings by Fenton Mary Kay

Jun 30, 2026: Grant or award of CGEM shares (Form 4, code A).
Feb 20, 2026: Open-market sale of CGEM shares (Form 4, code S).
Feb 18, 2026: Grant or award of CGEM shares (Form 4, code A).
Dec 31, 2025: Grant or award of CGEM shares (Form 4, code A).
Feb 19, 2025: Grant or award of CGEM shares (Form 4, code A).

Other insiders filing for Cullinan Therapeutics, Inc. (CGEM)

Michaelson Jennifer, Chief Scientific Officer
SUMER JACQUELYN L, Chief Legal Officer
Rosenberg Anthony, Director
Meek David D., Director
Webster Stephen W, Director
Allen Andrew R, Director

How to read Form 4 transaction codes